Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules.
Exogenous antigenic peptides captured and presented in the context of major histocompatibility (MHC) class II molecules on APC, have been employed as potent vaccine reagents capable of activating cellular immune responses. Binding and presentation of select peptide via surface class II molecules has been reported. Here, a role for endocytosis and early endosomes in the presentation of exogenous peptides via MHC class II molecules is described. T cell recognition of a 14 amino acid human serum albumin-derived peptide in the context of HLA-DR4 was observed only with metabolically active APC. The delayed kinetics and temperature dependence of functional peptide presentation via APC, were consistent with a requirement for peptide internalization to early endosomal compartments prior to T cell recognition. Ablating endocytosis by exposing cells to inhibitors of ATP production completely blocked the display of functional peptide:class II complexes on the surface of the APC. Presentation of the peptide was also found to be sensitive to primaquine, a drug that perturbs the recycling of transport vesicles containing endocytic receptors and mature class II complexes. Functional presentation of the endocytosed peptide was dependent upon these mature class II complexes, as inhibitor studies ruled out a requirement for newly synthesized class II molecules. N-terminal processing of the endocytosed peptide was observed upon trafficking through endosomal compartments and linked to the formation of functional peptide:class II complexes. These findings establish a novel mechanism for regulating class II-restricted peptide presentation via the endocytic pathway.
Pathak
S S
SS
Department of Microbiology and Immunology, Walther Oncology Center, Indiana University School of Medicine, IN, USA.
Blum
J S
JS
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D017951:Antigen Presentation / Q000502:physiology*; D000956:Antigens, Viral / Q000276:immunology / Q000378:metabolism*; D019921:Biotinylation; D020126:Brefeldin A / Q000494:pharmacology; D002460:Cell Line; D002738:Chloroquine / Q000494:pharmacology; D003847:Deoxyglucose / Q000494:pharmacology; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D005802:Genes, MHC Class II; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015804:HLA-DR4 Antigen / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D059811:HLA-DRB1 Chains; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D018942:Macrolides; D046911:Macromolecular Substances; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism*; D021381:Protein Transport / Q000187:drug effects; D012709:Serum Albumin / Q000276:immunology / Q000378:metabolism*; D016511:Severe Combined Immunodeficiency / Q000276:immunology / Q000473:pathology; D019810:Sodium Azide / Q000494:pharmacology; D014162:Transfection
D000900:Anti-Bacterial Agents; D000956:Antigens, Viral; D006684:HLA-DR Antigens; D015804:HLA-DR4 Antigen; D059811:HLA-DRB1 Chains; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D018942:Macrolides; D046911:Macromolecular Substances; D010446:Peptide Fragments; D012709:Serum Albumin; D020126:Brefeldin A; D002738:Chloroquine; C040929:bafilomycin A1; D019810:Sodium Azide; D003847:Deoxyglucose